Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

AstraZeneca

Status: Completed

Conditions: Hypertension; Diabetes; Coronary Heart Disease; Hypercholesterolemia; Peripheral Arterial Disease; Cardiovascular Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT01768403

NIS-CDZ-XXX-2012/1

Details and patient eligibility

About

Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the survey population.

Full description

Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia.

Enrollment: 1,236 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject must provide informed consent and comply with the survey procedures.
• Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion criteria

• Subjects who are unwilling or unable to provide informed consent.